Nasal Decongestant Maximum Strength

Nasal Decongestant Maximum Strength Manufacturers

• Chain Drug Consortium
  

  ×

  Nasal Decongestant Maximum Strength | Chain Drug Consortium

  

  ---

  adults and children
  12 years and older
   take 2 tablets every 4 to 6 hours;
   do not take more than 8 tablets in
   24 hours
  children ages
  6 to 12 years
  

   take 1 tablet every 4 to 6 hours;
   do not take more than 4 tablets in
   24 hours

  children under 6 years
   do not use this product in children
   under 6 years of age
  

  Close
  No Recall

  More Info
• Safeway
  

  ×

  Nasal Decongestant Maximum Strength | Cardinal Health

  

  ---

  2.1 Adult Patients

  The recommended dose of Meropenem for Injection I.V. is 500 mg given every 8 hours for skin and skin structure infections and 1 g given every 8 hours for intra-abdominal infections. Meropenem for Injection I.V. should be administered by intravenous infusion over approximately 15 to 30 minutes. Doses of 1 g may also be administered as an intravenous bolus injection (5 to 20 mL) over approximately 3 to 5 minutes.

  2.2 Use in Adult Patients with Renal Impairment

  Dosage should be reduced in patients with creatinine clearance of 50 mL/min or less. (See dosing table below.)

  When only serum creatinine is available, the following formula (Cockcroft and Gault equation)5 may be used to estimate creatinine clearance.

  Males: Creatinine Clearance (mL/min) = 

  Weight (kg) x (140 - age)

  72 x serum creatinine (mg/dL)

  Females: 0.85 x above value 

  Recommended Meropenem for Injection I.V. Dosage Schedule for Adult Patients with Renal Impairment

  Creatinine Clearance
  (mL/min)

  Dose (dependent on
  type of infection)

  Dosing Interval

  >50

  Recommended dose (500 mg cSSSI and 1 g Intra-abdominal)

  Every 8 hours

  >25 to 50

  Recommended dose

  Every 12 hours

  10 to 25

  One-half recommended dose

  Every 12 hours

  <10

  One-half recommended dose

  Every 24 hours

  There is inadequate information regarding the use of Meropenem for Injection I.V. in patients on hemodialysis or peritoneal dialysis.

  2.3 Use in Pediatric Patients (≥ 3 Months only)

  For pediatric patients from 3 months of age and older, the Meropenem for Injection I.V. dose is 10, 20 or 40 mg/kg every 8 hours (maximum dose is 2 g every 8 hours), depending on the type of infection (complicated skin and skin structure, intra-abdominal or meningitis). (See dosing table below.) Pediatric patients weighing over 50 kg should be administered Meropenem for Injection I.V. at a dose of 500 mg every 8 hours for complicated skin and skin structure infections, 1 g every 8 hours for intra-abdominal infections and 2 g every 8 hours for meningitis. Meropenem for Injection I.V. should be given as intravenous infusion over approximately 15 to 30 minutes or as an intravenous bolus injection (5 to 20 mL) over approximately 3 to 5 minutes.

  There is limited safety data available to support the administration of a 40 mg/kg (up to a maximum of 2 g) bolus dose.

  Recommended Meropenem for Injection I.V. Dosage Schedule for Pediatric Patients with Normal Renal Function

  Type of
  Infection

  Dose
  (mg/kg)

  Up to a Maximum
  Dose

  Dosing
  Interval

  Complicated skin and skin structure

  10

  500 mg

  Every 8 hours

  Intra-abdominal

  20

  1 g

  Every 8 hours

  Meningitis

  40

  2 g

  Every 8 hours

  There is no experience in pediatric patients with renal impairment. 

  2.4 Preparation of Solution

  For Intravenous Bolus Administration

  Constitute injection vials (500 mg and 1 g) with sterile Water for Injection. (See table below.) Shake to dissolve and let stand until clear.

  Vial size

  Amount of Diluent
  Added (mL)

  Approximate Withdrawable Volume
  (mL)

  Approximate Average
  Concentration
  (mg/mL)

  500 mg

  10

  10

  50

  1 g

  20

  20

  50

  For Infusion

  Infusion vials (500 mg and 1 g) may be directly constituted with a compatible infusion fluid. Alternatively, an injection vial may be constituted, then the resulting solution added to an I.V. container and further diluted with an appropriate infusion fluid [see Dosage and Administration (2.5) and (2.6)].

  WARNING: Do not use flexible container in series connections.

  2.5 Compatibility

  Compatibility of Meropenem with other drugs has not been established. Meropenem should not be mixed with or physically added to solutions containing other drugs.

  2.6 Stability and Storage

  Freshly prepared solutions of Meropenem should be used whenever possible. However, constituted solutions of Meropenem maintain satisfactory potency at controlled room temperature 15 to 25ºC (59 to 77ºF) or under refrigeration at 4°C (39°F) as described below. Solutions of intravenous Meropenem should not be frozen.

  Intravenous Bolus Administration

  Meropenem for Injection I.V. vials constituted with sterile Water for Injection for bolus administration (up to 50 mg/mL of Meropenem) may be stored for up to 2 hours at controlled room temperature 15 to 25°C (59 to 77°F) or for up to 12 hours at 4°C (39°F).

  Intravenous Infusion Administration

  Stability in Infusion Vials:

  Meropenem for Injection I.V. infusion vials constituted with Sodium Chloride Injection 0.9% (Meropenem concentrations ranging from 2.5 to 50 mg/mL) are stable for up to 2 hours at controlled room temperature 15 to 25°C (59 to 77°F) or for up to 18 hours at 4°C (39°F). Infusion vials of Meropenem for Injection I.V. constituted with Dextrose Injection 5% (Meropenem concentrations ranging from 2.5 to 50 mg/mL) are stable for up to 1 hour at controlled room temperature 15 to 25°C (59 to 77°F) or for up to 8 hours at 4°C (39°F).

  Stability in Plastic I.V. Bags:

  Solutions prepared for infusion (Meropenem concentrations ranging from 1 to 20 mg/mL) may be stored in plastic intravenous bags with diluents as shown below:

  Number of Hours Stable at Controlled Room
  Temperature
  15 to 25°C (59 to 77°F)

  Number of Hours Stable
  at 4°C (39°F)

  Sodium Chloride Injection 0.9%

  4

  24

  Dextrose Injection 5%

  1

  4

  Dextrose Injection 10%

  1

  2

  Dextrose and Sodium Chloride Injection 5%/0.9%

  1

  2

  Dextrose and Sodium Chloride Injection 5%/0.2%

  1

  4

  Potassium Chloride in Dextrose Injection 0.15%/5%

  1

  6

  Sodium Bicarbonate in Dextrose Injection 0.02%/5%

  1

  6

  Dextrose Injection 5% in NormosolTM-M

  1

  8

  Dextrose Injection 5% in Ringers Lactate Injection

  1

  4

  Dextrose and Sodium Chloride Injection 2.5%/0.45%

  3

  12

  Mannitol Injection 2.5%

  2

  16

  Ringers Injection

  4

  24

  Ringers Lactate Injection

  4

  12

  Sodium Lactate Injection 1/6 N

  2

  24

  Sodium Bicarbonate Injection 5%

  1

  4

  Stability in Baxter Minibag Plus® (manufactured by Baxter, Inc.):

  Solutions of Meropenem (Meropenem concentrations ranging from 2.5 to 20 mg/mL) in Baxter Minibag Plus bags® (manufactured by Baxter, Inc.) with Sodium Chloride Injection 0.9% may be stored for up to 4 hours at controlled room temperatures 15 to 25°C (59 to 77°F) or for up to 24 hours at 4°C (39°F). Solutions of Meropenem (Meropenem concentrations ranging from 2.5 to 20 mg/mL) in Baxter Minibag Plus bags® (manufactured by Baxter, Inc.) with Dextrose Injection 5% may be stored up to 1 hour at controlled room temperatures 15 to 25°C (59 to 77°F) or for up to 6 hours at 4°C (39°F).

  Stability in Plastic Syringes, Tubing and Intravenous Infusion Sets:

  Solutions of Meropenem (Meropenem concentrations ranging from 1 to 20 mg/mL) in Water for Injection or Sodium Chloride Injection 0.9% (for up to 4 hours) or in Dextrose Injection 5% (for up to 2 hours) at controlled room temperatures 15 to 25°C (59 to 77°F) are stable in plastic tubing and volume control devices of common intravenous infusion sets.

  Solutions of Meropenem (Meropenem concentrations ranging from 1 to 20 mg/mL) in Water for Injection or Sodium Chloride Injection 0.9% (for up to 48 hours) or in Dextrose Injection 5% (for up to 6 hours) are stable at 4ºC (39ºF) in plastic syringes.

  NOTE: Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. 

  Close
  No Recall

  More Info
• P And L Development Of New York Corporation (Readyincase)
  

  ×

  Nasal Decongestant Maximum Strength | P And L Development Of New York Corporation (readyincase)

  

  ---

  adults and children 12 years and over: take 1 tablet every 4 hours. Do not take more than 6 tablets in 24 hours. children under 12 years: do not use this product for children under 12 years of age

  Close
  No Recall

  More Info
• Live Better (The Great Atlantic & Pacific Tea Company)
  

  ×

  Nasal Decongestant Maximum Strength | Live Better (the Great Atlantic & Pacific Tea Company)

  

  ---

  adults and children 12 years and over: take 1 tablet every 4 hours. Do not take more than 6 tablets in 24 hours. children under 12 years: do not use this product for children under 12 years of age

  Close
  No Recall

  More Info